

## Olumiant

Oman · access guide

# How to access Olumiant from Oman, the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

An Oman patient with moderate-to-severe rheumatoid arthritis, severe alopecia areata, or select inflammatory indications may receive a prescription for Olumiant (baricitinib) from their treating rheumatologist or dermatologist. Olumiant is FDA-approved in the United States and commercialised by Eli Lilly (originally developed with Incyte). It is an oral, once-daily JAK1/JAK2 inhibitor, the first FDA-approved systemic therapy for severe alopecia areata, and a well-established option in rheumatoid arthritis after inadequate response to methotrexate or biologic therapy. Access in Oman varies by state, by institution, and by indication; when locally available strengths or formulations do not match the prescribed regimen, a DGPADC personal-use import pathway remains legitimate for the patient whose physician has already prescribed the drug.

This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.

## The clinical situation

Olumiant is an oral JAK1/JAK2 inhibitor taken once daily. Usual adult dosing is 2 mg once daily for rheumatoid arthritis, with 4 mg used for severe alopecia areata and in certain rheumatoid cases with inadequate response at the 2 mg dose. Pre-treatment workup per FDA labeling includes tuberculosis screening, hepatitis B and C serology, CBC with differential, lipid panel, and liver function tests; vaccination status (including consideration of live vaccines) is reviewed. The FDA boxed warning shared across the JAK class covers serious infections, malignancy, major adverse cardiovascular events, thrombosis, and mortality in certain rheumatoid arthritis populations over age 50 with at least one cardiovascular risk factor. Your physician will walk through that risk profile before starting therapy and schedule ongoing lab and clinical monitoring.

## Is Olumiant legally importable into Oman?

Yes, through the Central Drugs Standard Control Organization (DGPADC) personal-use / named-patient import framework, coordinated with the treating hospital or prescribing physician. The Oman has a long-standing personal-use import mechanism under the Drugs and Cosmetics Rules that supports access to medicines approved by reference authorities but not locally registered for the specific indication or not locally available in the needed strength.

The DGPADC pathway allows a qualified Omann physician to support import of a medicine when: (a) the medicine is approved by a recognised reference authority such as the US FDA or EMA, (b) no clinically equivalent locally available alternative is suitable for the patient, (c) the treating physician takes clinical responsibility and a valid prescription is in hand, and (d) chain of custody is documented from the US source to the patient or dispensing facility. Quantities imported are typically bounded by a defined treatment duration.

## How the pathway works, step by step

---

1. **Consultation with your treating physician.** The prescribing decision is clinical. Your physician documents the indication, severity, prior therapies, and rationale for Olumiant.
2. **Baseline screening.** TB, viral hepatitis, CBC, lipid panel, LFTs, and vaccination review are completed and documented.
3. **DGPADC personal-use documentation.** Your physician writes a prescription and supporting letter; Reserve Meds's regulatory team packages the import documentation.
4. **US-side sourcing.** Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from Eli Lilly's authorised distribution under DSCSA chain-of-custody.
5. **Shipment.** Olumiant is an oral tablet with standard room-temperature storage; shipment moves with tamper-evident packaging and tracking documentation through Omann customs under the personal-use allowance.
6. **Arrival and first dose.** Product reaches the patient or dispensing pharmacy against the physician's prescription and therapy begins on schedule.

## What documentation your physician needs

---

Your physician will typically need to provide:

- A clinical rationale letter confirming diagnosis (RA, severe alopecia areata, or other indication), severity scoring, prior therapy history, and Olumiant as the indicated treatment
- Verification of their Omann medical registration (MCI / NMC / state council)
- A patient identifier on the prescription
- Documented pre-treatment screening (TB, hepatitis, CBC, lipids, LFTs) consistent with FDA labeling
- The planned dosing strength (2 mg or 4 mg) and treatment duration
- A discussion note on JAK-class cardiovascular and malignancy risk appropriate for the patient profile

Reserve Meds provides a physician documentation kit that bundles templates typical for DGPADC personal-use imports and reflects JAK-class labeling expectations.

## Typical costs and indicative timing

---

Reserve Meds gives you a drug-only reference range plus a transparent delivered quote at intake. As an illustrative composite case, the US cash-pay reference range for a 30-tablet month supply of Olumiant 2 mg sits in an indicative 2026 band of roughly USD 2,800 to 3,500, with the 4 mg strength running higher. International logistics, DGPADC documentation handling, customs clearance, and concierge coordination add incremental cost. The delivered quote we issue at intake itemises each line so nothing is hidden.

Indicative timing, not a guarantee, for first dose after cohort intake opens is 7 to 14 days from the moment a complete documentation package is finalised, assuming customs clears on first pass. Refills ship on a rolling cadence.

; service availability is limited to our first cohort. All timelines are indicative, not guarantees. If your clinical situation is time-sensitive, flag that when you

## Where Reserve Meds fits in

---

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Olumiant specifically, we provide:

- **Sourcing.** Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- **Documentation.** DGPADC-oriented personal-use package tailored for your physician and for Omann customs clearance.
- **Logistics.** Tamper-evident, internationally tracked shipment to your address or dispensing pharmacy.
- **Concierge case lead.** A named point of contact for your family and your physician across the full case arc.

We are a coordinator, not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician, and dispensing sits with the licensed pharmacy of record.

## FAQ

---

### Is this legal in Oman?

Yes, when executed through the DGPADC personal-use / named-patient framework with a valid prescription, appropriate clinical rationale, and complete customs documentation.

### Is a generic baricitinib available in Oman?

The Omann generics market is dynamic. If a locally available baricitinib product meets your physician's clinical specification, it may be the right choice. Reserve Meds is relevant where the US brand is specifically prescribed, a specific strength is needed, or the physician's rationale requires the reference-listed product.

### What about the JAK boxed warning?

The FDA boxed warning on JAK inhibitors covers serious infections, malignancy, major adverse cardiovascular events, and thrombosis. Your physician performs the risk-benefit assessment before starting therapy and monitors per labeling.

### Can I use Olumiant for alopecia areata in Oman?

FDA-approved for severe alopecia areata; your dermatologist makes the clinical call for your case. The named-patient / personal-use pathway supports the import when the US product is specifically prescribed.

### Will private insurance cover this?

Cash-pay is the default posture. Some Omann private insurers reimburse specialty imports on a case-by-case basis; we supply documentation so you can submit, but we do not process insurance claims directly.

## ***Reserve Meds's role***

US-based concierge coordinator for cross-border specialty medicine. We are not the prescriber, not the dispensing pharmacy, and not the manufacturer. All clinical decisions remain with your treating physician.

---

### **Reserve Meds**

*reserved for you.*

Composite case examples. This document is for general information only and does not constitute medical advice. Please consult your treating physician.

Reserve Meds is in pre-launch. Published timelines and cost ranges are indicative, not guarantees.

reservemeds.com · hello@reservemeds.com